Novartis Faces Key Risks Despite Promising New Multiple Sclerosis Drug
Novartis AG (NYSE:NVS) has reported encouraging Phase 3 trial results for its experimental drug remibrutinib in treating relapsing multiple sclerosis. The trials showed the drug reduced relapse activity and inflammatory brain lesions, meeting primary endpoints with a favorable safety profile. Analysts estimate that if approved, remibrutinib could generate up to $3 billion annually from MS alone or over $10 billion across all indications. The global MS therapeutics market is expected to grow at 5.9% CAGR and reach nearly $38.6 billion by 2030. Novartis already has a strong presence in the space with Kesimpta, which saw second-quarter sales of $1.42 billion, up from last year. However, risks remain for investors. Sustaining growth will depend on maintaining Kesimpta's market share and overcoming competition like Roche’s BTK inhibitor pipeline. Regulatory approval is still needed before remibrutinib can reach the market.
Tickers: $NVS
Topics: multiple sclerosis Novartis Phase 3 trial results remibrutinib